SCHEMBL14765168

SCHEMBL14765168

FC(F)(F)c1ccc(-c2nnc3ccc(Cl)nn23)cc1

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.64
ALDH1A1 P00352 2/20 0.62
DYRK1A Q13627 2/20 0.59
DYRK2 Q92630 2/20 0.59
PIM1 P11309 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.56
LRRK2 Q5S007 9/20 0.55
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CDK5 Q00535 1/20 0.45
CDK5R1 Q15078 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
SCN5A Q14524 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16455949 0.85 ALDH1A1 (0.50) KDM4EALDH1A1DYRK1ADYRK2PIM1
SCHEMBL32664904 0.83 CDK2 (0.63) KDM4EALDH1A1DYRK1ADYRK2PIM1
SCHEMBL15365749 0.83 HSD17B10 (0.58) KDM4EALDH1A1PIM1SMN1; SMN2LRRK2
SCHEMBL32664934 0.82 ALDH1A1 (0.56) KDM4EALDH1A1PIM1SMN1; SMN2NPSR1
SCHEMBL16456325 0.81 KDM4E (0.55) KDM4EALDH1A1PIM1SMN1; SMN2
SCHEMBL14852007 0.80 HPGD (0.53) KDM4EALDH1A1PIM1SMN1; SMN2
SCHEMBL4784567 0.79 BRD4 (0.65) KDM4EALDH1A1DYRK1APIM1SMN1; SMN2
SCHEMBL12204663 0.78 KDM4E (1.00) KDM4EALDH1A1DYRK1ADYRK2PIM1
SCHEMBL750158 0.77 ALDH1A1 (1.00) KDM4EALDH1A1DYRK1ADYRK2SMN1; SMN2
SCHEMBL24095114 0.76 ALDH1A1 (0.51) KDM4EALDH1A1DYRK1ADYRK2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS UNIV MINNESOTA (US) 2026-01-22 US disclosed
EP-2753611-B1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME (US) 2018-04-11 EP disclosed
EP-2753611-B1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME (US) 2018-04-11 EP disclosed
US-20150246902-A1 SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2015-09-03 US disclosed
US-20150246902-A1 SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2015-09-03 US disclosed
WO-2013034048-A1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2013-03-14 WO disclosed
WO-2013034048-A1 SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2013-03-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022124-A1 THERAPEUTIC COMPOUNDS AND METHODS NR5A1, CYP17A1, CNR1 KDM4E 1972/4885ALDH1A1 663/4885DYRK1A 4505/4885
US-20150246902-A1 SUBSTITUED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES EIF5B, EIF2AK2, HCCS KDM4E 2423/4885ALDH1A1 158/4885DYRK1A 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.